GlassScriptPhysician profile
Mouhammed Sheikha
NPI 1619986387
$1,465.31
in general payments reported to CMS, 2019-2025
22 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2022: $34.27 · 2023: $387 · 2024: $332 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $261.86 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $251.42 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $137.44 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $92.18 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $87.06 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $82.48 | 2023-2025 | Arexvy, Shingrix |
| Exact Sciences Corporation | $80.43 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $79.01 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $72.33 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $55.97 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.21 | 2022-2024 | Xifaxan |
| Amgen INC. | $36.05 | 2019 | |
| Allergan, INC. | $29.99 | 2019 | |
| Corcept Therapeutics | $28.30 | 2025 | Korlym |
| Melinta Therapeutics, LLC | $22.58 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $18.32 | 2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2023 | |
| Xeris Pharmaceuticals, INC. | $16.99 | 2025 | Gvoke Hypopen |
| Dexcom, INC. | $16.60 | 2024 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $15.96 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.14 | 2019 | |
| Mayne Pharma Commercial LLC | $6.45 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mouhammed Sheikha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.